From the Clinical and Population Health Research Program, Graduate School of Biomedical Sciences, and the Division of Epidemiology of Chronic Diseases and Vulnerable Populations, Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Departments of Family Medicine and Epidemiology, Warren Alpert Medical School and School of Public Health, Brown University, Providence; Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island; Division of Rheumatology, Tufts Medical Center, Boston, Massachusetts, USA.
S.H. Liu, PhD, Clinical and Population Health Research Program, Graduate School of Biomedical Sciences, and the Division of Epidemiology of Chronic Diseases and Vulnerable Populations, Department of Quantitative Health Sciences, University of Massachusetts Medical School; C.E. Dubé, EdD, Division of Epidemiology of Chronic Diseases and Vulnerable Populations, Department of Quantitative Health Sciences, University of Massachusetts Medical School; C.B. Eaton, MD, Departments of Family Medicine and Epidemiology, Warren Alpert Medical School and School of Public Health, and Center for Primary Care and Prevention, Memorial Hospital of Rhode Island; J.B. Driban, PhD, Division of Rheumatology, Tufts Medical Center; T.E. McAlindon, MD, Division of Rheumatology, Tufts Medical Center; K.L. Lapane, PhD, Division of Epidemiology of Chronic Diseases and Vulnerable Populations, Department of Quantitative Health Sciences, University of Massachusetts Medical School.
J Rheumatol. 2018 Aug;45(9):1316-1324. doi: 10.3899/jrheum.171385. Epub 2018 Jun 15.
We examined the longterm effectiveness of corticosteroid or hyaluronic acid injections in relieving symptoms among persons with knee osteoarthritis (OA).
Using Osteoarthritis Initiative data, a new-user design was applied to identify participants initiating corticosteroid or hyaluronic acid injections (n = 412). Knee symptoms (pain, stiffness, function) were measured using The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We used marginal structural models adjusting for time-varying confounders to estimate the effect on symptoms of newly initiated injection use compared to nonusers over 2 years of followup.
Among 412 participants initiating injections, 77.2% used corticosteroid injections and 22.8% used hyaluronic acid injections. About 18.9% had additional injection use after initiation, but switching between injection types was common. Compared to nonusers, on average, participants initiating a corticosteroid injection experienced a worsening of pain (yearly worsening: 1.24 points, 95% CI 0.82-1.66), stiffness (yearly worsening: 0.30 points, 95% CI 0.10-0.49), and physical functioning (yearly worsening: 2.62 points, 95% CI 0.94-4.29) after adjusting for potential confounders with marginal structural models. Participants initiating hyaluronic acid injections did not show improvements of WOMAC subscales (pain: 0.50, 95% CI -0.11 to 1.11; stiffness: -0.07, 95% CI -0.38 to 0.24; and functioning: 0.49, 95% CI -1.34 to 2.32).
Although intraarticular injections may support the effectiveness of reducing symptoms in short-term clinical trials, the initiation of corticosteroid or hyaluronic acid injections did not appear to provide sustained symptom relief over 2 years of followup for persons with knee OA.
我们研究了皮质类固醇或透明质酸注射在缓解膝骨关节炎(OA)患者症状方面的长期效果。
利用骨关节炎倡议数据,采用新用户设计,确定开始皮质类固醇或透明质酸注射(n=412)的参与者。使用西安大略和麦克马斯特大学骨关节炎指数(WOMAC)测量膝关节症状(疼痛、僵硬、功能)。我们使用边缘结构模型调整随时间变化的混杂因素,估计与非使用者相比,在 2 年的随访期间新开始注射使用对症状的影响。
在 412 名开始注射的参与者中,77.2%使用皮质类固醇注射,22.8%使用透明质酸注射。大约 18.9%在开始后有额外的注射使用,但注射类型之间的转换很常见。与非使用者相比,平均而言,开始皮质类固醇注射的参与者在疼痛(每年恶化:1.24 分,95%CI 0.82-1.66)、僵硬(每年恶化:0.30 分,95%CI 0.10-0.49)和身体功能(每年恶化:2.62 分,95%CI 0.94-4.29)方面的恶化,在调整边缘结构模型中的潜在混杂因素后。开始透明质酸注射的参与者在 WOMAC 子量表上没有显示出改善(疼痛:0.50,95%CI-0.11 至 1.11;僵硬:-0.07,95%CI-0.38 至 0.24;功能:0.49,95%CI-1.34 至 2.32)。
尽管关节内注射可能在短期临床试验中支持减轻症状的效果,但皮质类固醇或透明质酸注射的开始似乎并不能在 2 年的随访中为膝骨关节炎患者提供持续的症状缓解。